Cancer Center Clínica Universidad de Navarra (CCUN)
Centro clínico de la Universidad de Navarra
University of Glasgow
Glasgow, Reino UnidoPublications en collaboration avec des chercheurs de University of Glasgow (48)
2024
-
Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling
Nature Communications, Vol. 15, Núm. 1
-
Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft models
Nature Communications , Vol. 15, Núm. 1
-
The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma
Nature Cancer, Vol. 5, Núm. 2, pp. 347-363
2023
-
An engineered periosteum for efficient delivery of rhBMP-2 and mesenchymal progenitor cells during bone regeneration
npj Regenerative Medicine, Vol. 8, Núm. 1
-
Antibodies against endogenous retroviruses promote lung cancer immunotherapy
Nature, Vol. 616, Núm. 7957, pp. 563-573
-
Body composition and lung cancer-associated cachexia in TRACERx
Nature Medicine, Vol. 29, Núm. 4, pp. 846-858
-
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance
Nature Reviews Gastroenterology and Hepatology, Vol. 20, Núm. 7, pp. 462-480
-
Evolutionary characterization of lung adenocarcinoma morphology in TRACERx
Nature Medicine
-
Genomic–transcriptomic evolution in lung cancer and metastasis
Nature, Vol. 616, Núm. 7957, pp. 543-552
-
Lung adenocarcinoma promotion by air pollutants
Nature, Vol. 616, Núm. 7955, pp. 159-167
-
The evolution of lung cancer and impact of subclonal selection in TRACERx
Nature, Vol. 616, Núm. 7957, pp. 525-533
-
The evolution of non-small cell lung cancer metastases in TRACERx
Nature, Vol. 616, Núm. 7957, pp. 534-542
-
Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA
Nature, Vol. 616, Núm. 7957, pp. 553-562
2022
-
A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer
Nature Cancer, Vol. 3, Núm. 6, pp. 696-709
-
Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry
Journal of Hepatology, Vol. 76, Núm. 5, pp. 1109-1121
-
Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions
Gut, Vol. 71, Núm. 8, pp. 1669-1683
-
EPIK-O/ENGOT-OV61: alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study)
Future oncology (London, England), Vol. 18, Núm. 31, pp. 3481-3492
-
New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming
Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1
-
Validation of the OAKS prognostic model for acute kidney injury after gastrointestinal surgery
BJS Open, Vol. 6, Núm. 1
2021
-
Assessing the impact of COVID-19 on liver cancer management (CERO-19)
JHEP Reports, Vol. 3, Núm. 3